Richard F. Riedel
Elite in Liposarcoma

Dr. Richard F. Riedel

Oncology
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
On Staff At
Accepting New Patients
Offers Telehealth

Elite in Liposarcoma
Duke Health
Duke Cancer Center
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I am a medical oncologist who focuses on bone and soft tissue cancers called sarcomas. I love spending time with my patients. They often have a sense of awareness about their condition that’s truly unique and rewarding. I partner with each patient so they know the full set of options available for treatment and can make an informed decision about the approach that is best for them. I’ve wanted to pursue medicine for as long as I can remember. I find cancer fascinating because of its ability to evade the immune system. The body fails to recognize cancer as being foreign. When I am not at work, I love spending time with my family and enjoy long distance running.

Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 3 clinical trials in the study of Liposarcoma.

Specialties
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Med, Internal Medicine
American Board Of Internal Med, Medical Oncology
Fellowships
Hematology-Medical Oncology, Duke University Medical Center
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Duke Cancer Center
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-681-6900

Additional Areas of Focus

Dr. Riedel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Gastrointestinal Stromal Tumor

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Enrollment Status: Terminated
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: TK216
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

79 Total Publications

Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032.
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
View All 79 Publications
Similar Doctors
Juneko E. Grilley-Olson
Distinguished in Liposarcoma
Dr. Juneko E. Grilley-Olson
Hematology Oncology | Hematology | Oncology
Distinguished in Liposarcoma
Dr. Juneko E. Grilley-Olson
Hematology Oncology | Hematology | Oncology

Duke Cancer Center Sarcoma Clinic

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-613-5550
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I am a medical oncologist specializing in bone and soft tissue cancers called sarcomas. Sarcomas occur throughout the body, so I collaborate closely with colleagues from other specialties in a multidisciplinary team. I view my role in caring for someone's cancer as as privilege and strive to work together with each patient to ensure the best treatment decisions are made, all the while embracing each person's uniqueness as an individual. I see adult patients of all ages, but have a particular interest in the unique challenges facing a young adults with cancer. When I'm not working, you can find me exploring the outdoors with my family, traveling, and cooking. Dr. Grilley-Olson is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Fibrosarcoma.

Jeffrey A. Crawford
Advanced in Liposarcoma
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology
Advanced in Liposarcoma
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

When someone is faced with a diagnosis of lung cancer, they may be going through surgery, radiation treatment, chemotherapy or enrolling in a clinical trial. It’s a very complicated process to understand what’s involved and what may happen next. It’s also hard to hear all the answers if you’re by yourself. We encourage our patients to come with family members and friends and loved ones and particularly to identify one or two main go-to people in terms of care-giving and support. That way we can engage them in the whole process. Just as we have a team taking care of the patient, the patient has a team, too. At Duke, we have the opportunity to engage patients in the very latest treatment approaches, whether it’s a new surgical technique, the latest radiation approach, or some novel chemotherapy, immunology, or targeted therapy, several of which we’ve been developing. Duke provides patients with a real opportunity that they may not have elsewhere. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and ALK-Positive Non-Small Cell Lung Cancer.

Experienced in Liposarcoma
Dr. Mark G. Woodcock
Hematology | Oncology
Experienced in Liposarcoma
Dr. Mark G. Woodcock
Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Woodcock is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Woodcock is rated as an Advanced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Triple-Negative Breast Cancer, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Gastrointestinal Stromal Tumor. Dr. Woodcock is currently accepting new patients.

VIEW MORE LIPOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Riedel's expertise for a condition
ConditionClose
  • Elite
  • Adult Soft Tissue Sarcoma
    Dr. Riedel is
    Elite
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Angiosarcoma
    Dr. Riedel is
    Elite
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Desmoid Tumor
    Dr. Riedel is
    Elite
    . Learn about Desmoid Tumor.
    See more Desmoid Tumor experts
  • Gastrointestinal Stromal Tumor
    Dr. Riedel is
    Elite
    . Learn about Gastrointestinal Stromal Tumor.
    See more Gastrointestinal Stromal Tumor experts
  • Liposarcoma
    Dr. Riedel is
    Elite
    . Learn about Liposarcoma.
    See more Liposarcoma experts
  • Undifferentiated Pleomorphic Sarcoma
    Dr. Riedel is
    Elite
    . Learn about Undifferentiated Pleomorphic Sarcoma.
    See more Undifferentiated Pleomorphic Sarcoma experts
  • Distinguished
  • Alveolar Soft Part Sarcoma
    Dr. Riedel is
    Distinguished
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Angiosarcoma of the Scalp
    Dr. Riedel is
    Distinguished
    . Learn about Angiosarcoma of the Scalp.
    See more Angiosarcoma of the Scalp experts
  • Bone Tumor
    Dr. Riedel is
    Distinguished
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chondrosarcoma
    Dr. Riedel is
    Distinguished
    . Learn about Chondrosarcoma.
    See more Chondrosarcoma experts
  • Epithelioid Sarcoma
    Dr. Riedel is
    Distinguished
    . Learn about Epithelioid Sarcoma.
    See more Epithelioid Sarcoma experts
  • Ewing Sarcoma
    Dr. Riedel is
    Distinguished
    . Learn about Ewing Sarcoma.
    See more Ewing Sarcoma experts
View All 19 Distinguished Conditions
  • Advanced
  • Desmoplastic Small Round Cell Tumor
    Dr. Riedel is
    Advanced
    . Learn about Desmoplastic Small Round Cell Tumor.
    See more Desmoplastic Small Round Cell Tumor experts
  • Lung Cancer
    Dr. Riedel is
    Advanced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Malignant Peripheral Nerve Sheath Tumor
    Dr. Riedel is
    Advanced
    . Learn about Malignant Peripheral Nerve Sheath Tumor.
    See more Malignant Peripheral Nerve Sheath Tumor experts
  • Pleuropulmonary Blastoma
    Dr. Riedel is
    Advanced
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
  • Pseudomyxoma Peritonei
    Dr. Riedel is
    Advanced
    . Learn about Pseudomyxoma Peritonei.
    See more Pseudomyxoma Peritonei experts
  • Experienced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Riedel is
    Experienced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Agranulocytosis
    Dr. Riedel is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Riedel is
    Experienced
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Brain Tumor
    Dr. Riedel is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. Riedel is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Chordoma
    Dr. Riedel is
    Experienced
    . Learn about Chordoma.
    See more Chordoma experts
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.